```html

Xanthopsia‑Related Color Vision Defect

What is Xanthopsia‑Related Color Vision Defect?

Xanthopsia is a type of dyschromatopsia in which the affected individual perceives a yellow‑tinted world. When the yellow tint is the dominant distortion of the normal color spectrum, clinicians refer to this pattern as a Xanthopsia‑related color vision defect. It is not a disease itself but a symptom that reflects underlying changes in the retina, optic nerve, or central visual pathways that alter the way photoreceptor cells process short‑wavelength (blue) light.<sup>1</sup>

People with xanthopsia often report that whites appear creamy or buttery, blues look greenish, and reds may seem orange. The defect may be constant or intermittent, and its intensity can vary from a faint hue to a striking yellow veil that impairs daily activities such as reading, driving, or distinguishing traffic signals.

Common Causes

Several medical conditions, medications, and environmental factors can produce a yellow‑tinged color vision defect. The most frequently encountered causes include:

• Medication toxicity – especially digoxin, quinine, phenothiazines, and some antiepileptics.
• Retinal diseases – age‑related macular degeneration (dry form), central serous chorioretinopathy, and cataracts with yellowing of the lens.
• Vitamin A excess or deficiency – hypervitaminosis A can alter photoreceptor function, while severe deficiency can cause retinal degeneration.
• Posterior uveitis – inflammatory conditions such as sarcoidosis or infectious uveitis can change the hue of the visual field.
• Leber congenital amaurosis (LCA) and other inherited retinal dystrophies – genetic defects affecting the cone phototransduction cascade.
• Neurological lesions – tumors or stroke affecting the optic radiations or visual cortex, particularly the V4 area responsible for color processing.
• Chronic liver disease – accumulation of bilirubin and other pigments can cause a yellowish discoloration of the ocular media.
• Exposure to certain chemicals – prolonged contact with solvents (e.g., carbon tetrachloride) or heavy metals like lead.
• Age‑related changes – natural yellowing of the crystalline lens and decreased blue‑light transmission.
• Phototoxic injury – intense UV or blue‑light exposure causing selective damage to S‑cones.

Identifying the precise etiology is crucial because treatment hinges on addressing the underlying cause.

Associated Symptoms

While the hallmark of xanthopsia is a yellow tint, patients often experience a constellation of other visual and systemic signs, such as:

• Reduced visual acuity or blurred vision.
• Glare or difficulty seeing in bright daylight.
• Difficulty distinguishing traffic lights, especially the green signal.
• Photopsia (flashes of light) or halos around lights.
• Eye discomfort, dryness, or a gritty sensation.
• Headache or eye strain after prolonged reading or screen time.
• Systemic clues related to the cause (e.g., palpitations with digoxin toxicity, jaundice with liver disease).

When to See a Doctor

Because a color vision defect can herald serious ocular or systemic disease, timely evaluation is essential. Seek professional care if you notice any of the following:

• Sudden onset of the yellow tint, especially if it progresses rapidly.
• Accompanying loss of visual acuity, double vision, or visual field cuts.
• Persistent headaches, nausea, or dizziness with the visual change.
• Recent start or dosage change of medications known to affect color vision (e.g., digoxin).
• History of trauma, stroke, or neurological disease.
• Systemic symptoms such as jaundice, unexplained weight loss, or fever.
• Interference with daily activities like driving, reading, or operating machinery.

Prompt assessment can prevent irreversible damage and treat potentially life‑threatening conditions.

Diagnosis

Evaluation of xanthopsia involves a stepwise approach that combines history‑taking, ocular examination, and targeted investigations.

1. Detailed Medical History

• Medication list (including over‑the‑counter and herbal supplements).
• Onset, duration, and pattern of color change.
• Associated systemic symptoms (e.g., cardiac, hepatic, neurologic).
• Family history of inherited retinal disorders.

2. Visual Function Tests

• Snellen acuity chart – to document baseline sharpness.
• Ishihara plates & Farnsworth–Munsell 100 Hue test – quantitative assessment of color discrimination, often revealing a specific deficit for short‑wavelength colors.
• Contrast sensitivity testing – can uncover subtle functional loss not seen on acuity charts.

3. Slit‑Lamp Examination

Allows the clinician to inspect the cornea, anterior chamber, lens, and vitreous for cataract formation, lens yellowing, or inflammatory cells.

4. Dilated Fundus Examination

Using ophthalmoscopy or indirect imaging (fundus photography) to evaluate the retina, macula, and optic nerve for drusen, atrophy, or inflammatory lesions.

5. Ancillary Imaging

• Optical Coherence Tomography (OCT) – high‑resolution cross‑sectional images of the retina to detect macular thinning, sub‑retinal fluid, or photoreceptor loss.
• Fundus Autofluorescence (FAF) – highlights metabolic stress in the retinal pigment epithelium.
• Fluorescein Angiography – useful if vascular leakage or choroidal neovascularization is suspected.
• Visual Evoked Potentials (VEP) – assess the integrity of the visual pathway when a neurological cause is considered.

6. Laboratory Tests (when indicated)

• Serum digoxin level (if on cardiac glycosides).
• Liver function panel and bilirubin (for hepatic etiologies).
• Vitamin A and B12 levels.
• Genetic testing for inherited retinal dystrophies.

Treatment Options

Treatment is directed at the underlying cause; however, supportive measures can improve visual comfort while the primary issue is being resolved.

1. Medication‑Related Causes

• Adjust or discontinue the offending drug under physician supervision (e.g., reduce digoxin dose).
• Substitute with alternative agents when possible.

2. Cataract‑Related Yellowing

• Phacoemulsification with intra‑ocular lens implantation is the definitive treatment, restoring normal color perception in >90% of cases.<sup>2</sup>

3. Retinal Disease Management

• Age‑Related Macular Degeneration: Anti‑VEGF intravitreal injections for neovascular type; nutritional supplementation (AREDS2 formula) for dry type.
• Central Serous Chorioretinopathy: Observation, photodynamic therapy, or eplerenone in chronic cases.
• Inflammatory Uveitis: Corticosteroids (topical, peri‑ocular, or systemic) and immunomodulatory agents.

4. Systemic Disease Treatment

• Manage liver disease (lifestyle modification, antiviral therapy for viral hepatitis, or transplantation when indicated).
• Correct vitamin deficiencies with oral supplementation.
• Address cardiovascular toxicity with cardiac monitoring and drug level adjustments.

5. Visual Rehabilitation

• Prescription of tinted glasses (e.g., blue‑blocking lenses) can reduce glare and improve contrast.
• Low‑vision aids – magnifiers, high‑contrast reading materials, and screen‑reading software.
• Occupational therapy to adapt daily tasks.

6. Lifestyle & Home Measures

• Adopt a diet rich in lutein, zeaxanthin, and omega‑3 fatty acids to support retinal health.
• Use appropriate UV‑blocking sunglasses to prevent further phototoxic damage.
• Maintain optimal control of chronic diseases (diabetes, hypertension) that can exacerbate retinal pathology.

Prevention Tips

While some causes (genetic disorders, age‑related changes) cannot be fully prevented, many modifiable risk factors can be addressed:

• Medication vigilance: Review all prescriptions with your pharmacist or physician annually.
• Protect eyes from UV/blue light: Wear sunglasses with 400 nm UV protection and consider blue‑light filters for digital devices.
• Regular eye examinations: Adults should have a comprehensive dilated exam at least every two years; more frequent if you have risk factors.
• Healthy liver: Limit alcohol, avoid illicit drugs, and get vaccinated against hepatitis B.
• Control systemic diseases: Maintain blood pressure, blood sugar, and cholesterol within target ranges.
• Nutrition: Incorporate leafy greens, carrots, eggs, and fatty fish to supply antioxidants and essential fatty acids.
• Safety with chemicals: Use protective eyewear when handling solvents or heavy metals; follow occupational safety guidelines.

Emergency Warning Signs

If any of the following occur, seek emergency medical attention (call 911 or go to the nearest emergency department):

• Sudden, profound loss of vision in one or both eyes.
• Accompanied severe headache, vomiting, or loss of consciousness – possible stroke or intracranial hemorrhage.
• Rapid progression of yellow tint with pain, redness, or swelling of the eye (suggestive of acute angle‑closure glaucoma or severe uveitis).
• Chest pain, palpitations, or dizziness together with visual changes while on digoxin – risk of life‑threatening cardiac toxicity.
• Signs of systemic infection (fever, chills) in a patient with known ocular inflammation.

---

References:

1. Mayo Clinic. “Color vision deficiency.” Accessed May 2024. https://www.mayoclinic.org
2. Cleveland Clinic. “Cataract Surgery Outcomes.” 2023. https://my.clevelandclinic.org
3. American Academy of Ophthalmology. “Age‑Related Macular Degeneration Preferred Practice Pattern.” 2022.
4. World Health Organization. “Prevention of Blindness from Chronic Liver Disease.” 2021.
5. National Institutes of Health. “Vitamin A Toxicity.” 2020. https://ods.od.nih.gov

```